Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)
China · Delayed Price · Currency is CNY 31.39
+0.74 (2.41%)
Nov 5, 2026, 4:00 PM EST
SHA:688163 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 194.08 | 196.21 | 194.92 | 190.13 | 174.21 | 207.5 |
Other Revenue | - | - | - | 0.02 | 0.01 | 1.19 |
| 194.08 | 196.21 | 194.92 | 190.14 | 174.22 | 208.69 | |
Revenue Growth | -1.36% | 0.66% | 2.51% | 9.14% | -16.52% | 12.46% |
Cost of Revenue | 44.49 | 45 | 45.8 | 49.84 | 33.5 | 36.33 |
Gross Profit | 149.59 | 151.2 | 149.11 | 140.3 | 140.72 | 172.36 |
Selling, General & Admin | 71.77 | 77.46 | 76.71 | 74.35 | 73.71 | 62.81 |
Research & Development | 22.31 | 19.51 | 23.84 | 30.41 | 15.46 | 25.76 |
Other Operating Expenses | 2.95 | 1.88 | 1.68 | 1.53 | 1.21 | 1.45 |
Operating Expenses | 95.25 | 98.95 | 102.96 | 107.08 | 90.28 | 90.34 |
Operating Income | 54.34 | 52.25 | 46.15 | 33.22 | 50.45 | 82.03 |
Interest Expense | -0.06 | -0.18 | -0.43 | -0.65 | -0.68 | -0.71 |
Interest & Investment Income | 8.47 | 10.79 | 6.12 | 10.62 | 16.3 | 1.48 |
Currency Exchange Gain (Loss) | -0.08 | -0.08 | -0.03 | 0.12 | 0.49 | -0.12 |
Other Non Operating Income (Expenses) | -2.94 | -0.2 | 0.23 | -0.25 | 0.42 | -0.3 |
EBT Excluding Unusual Items | 59.74 | 62.59 | 52.04 | 43.06 | 66.97 | 82.38 |
Gain (Loss) on Sale of Investments | 3.06 | 1.41 | -4.97 | 2.59 | 2.62 | -0.79 |
Gain (Loss) on Sale of Assets | 0.04 | 0.02 | 0.41 | -0.01 | -0.07 | -0.25 |
Asset Writedown | -1.47 | - | - | - | - | - |
Other Unusual Items | -0.14 | 0.19 | 3.09 | -0.23 | 4.53 | 6.54 |
Pretax Income | 61.23 | 64.21 | 50.57 | 45.42 | 74.04 | 87.88 |
Income Tax Expense | 10.58 | 12.42 | 6.28 | 6.64 | 9.84 | 11.39 |
Earnings From Continuing Operations | 50.65 | 51.79 | 44.29 | 38.77 | 64.2 | 76.48 |
Net Income | 50.65 | 51.79 | 44.29 | 38.77 | 64.2 | 76.48 |
Net Income to Common | 50.65 | 51.79 | 44.29 | 38.77 | 64.2 | 76.48 |
Net Income Growth | 11.19% | 16.93% | 14.23% | -39.60% | -16.06% | 21.07% |
Shares Outstanding (Basic) | 108 | 108 | 108 | 108 | 102 | 81 |
Shares Outstanding (Diluted) | 108 | 108 | 108 | 108 | 102 | 81 |
Shares Change | -0.39% | -0.13% | 0.30% | 5.70% | 25.24% | 0.46% |
EPS (Basic) | 0.47 | 0.48 | 0.41 | 0.36 | 0.63 | 0.94 |
EPS (Diluted) | 0.47 | 0.48 | 0.41 | 0.36 | 0.63 | 0.94 |
EPS Growth | 11.62% | 17.07% | 13.89% | -42.86% | -32.98% | 20.51% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -29.21 | 0.93 | -9.12 | 4.15 | 41.46 | 64.68 |
Free Cash Flow Per Share | -0.27 | 0.01 | -0.08 | 0.04 | 0.41 | 0.80 |
Dividend Per Share | 0.260 | 0.380 | 0.320 | 0.200 | 0.750 | 0.900 |
Dividend Growth | -18.75% | 18.75% | 60.00% | -73.33% | -16.67% | - |
Gross Margin | 77.08% | 77.06% | 76.50% | 73.79% | 80.77% | 82.59% |
Operating Margin | 28.00% | 26.63% | 23.68% | 17.47% | 28.96% | 39.30% |
Profit Margin | 26.10% | 26.39% | 22.72% | 20.39% | 36.85% | 36.65% |
Free Cash Flow Margin | -15.05% | 0.47% | -4.68% | 2.18% | 23.79% | 30.99% |
EBITDA | 72.27 | 70.85 | 65.64 | 49.46 | 64.43 | 96.15 |
EBITDA Margin | 37.24% | 36.11% | 33.67% | 26.01% | 36.98% | 46.07% |
D&A For EBITDA | 17.93 | 18.6 | 19.49 | 16.24 | 13.98 | 14.12 |
EBIT | 54.34 | 52.25 | 46.15 | 33.22 | 50.45 | 82.03 |
EBIT Margin | 28.00% | 26.63% | 23.68% | 17.47% | 28.96% | 39.30% |
Effective Tax Rate | 17.27% | 19.34% | 12.41% | 14.62% | 13.29% | 12.97% |
Revenue as Reported | 21.07 | 196.21 | 194.92 | 190.14 | 174.22 | 208.69 |
Advertising Expenses | - | 22.6 | 21.26 | - | - | - |